SEM · Select Medical Holdings Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.45B | $5.19B | $6.66B | $6.33B | $6.20B | $5.53B |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $154.41M | $225.87M | $170.19M | $153.03M | $146.97M | $138.04M |
| Total Operating Expenses | $5.12B | $4.92B | $6.11B | $5.96B | $5.63B | $5.05B |
| D&A | $140.30M | $203.89M | $208.74M | $205.82M | $202.65M | $205.66M |
| Operating Income | $336.17M | $268.31M | $554.87M | $403.28M | $713.77M | $567.66M |
| Interest Expense | $117.94M | $128.60M | $198.64M | $169.11M | $135.99M | $153.01M |
| Income Tax | $58.22M | $44.78M | $82.63M | $62.55M | $129.77M | $111.87M |
| Net Income | $146.22M | $214.04M | $243.49M | $158.99M | $402.23M | $259.00M |
| EPS - Basic | $1.16 | $1.66 | $1.03 | $0.66 | $1.61 | $1.04 |
| EPS - Diluted | $1.16 | $1.66 | $1.03 | $0.66 | $1.61 | $1.04 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $26.52M | $59.69M | $84.01M | $97.91M | $74.31M | $577.06M |
| Accounts Receivable | $864.21M | $821.38M | $940.34M | $941.31M | $889.30M | $896.76M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $157.06M | $142.16M | $174.31M | $186.73M | $233.84M | $177.09M |
| Current Assets | $1.03B | $1.02B | $1.26B | $1.27B | $1.14B | $1.59B |
| Total Assets | $5.85B | $5.61B | $7.69B | $7.67B | $7.36B | $7.66B |
| Current Liabilities | $984.49M | $977.65M | $1.25B | $1.16B | $1.27B | $1.44B |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $3.82B | $3.61B | $6.12B | $6.27B | $6.00B | $6.00B |
| Stockholders' Equity | $1.71B | $1.68B | $1.29B | $1.12B | $1.11B | $1.06B |
| Retained Earnings | $837.02M | $770.15M | $751.86M | $581.01M | $593.25M | $553.24M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $346.47M | $517.86M | $582.06M | $284.82M | $401.23M | $1.03B |
| Investing Cash Flow | ($216.49M) | ($231.01M) | ($268.48M) | ($226.34M) | ($256.59M) | ($115.35M) |
| Financing Cash Flow | ($163.15M) | ($311.17M) | ($327.48M) | ($34.89M) | ($647.38M) | ($671.54M) |
| CapEx | $229.22M | $222.18M | $229.20M | $190.37M | $180.54M | $146.44M |
| Free Cash Flow | $117.24M | $295.69M | $352.86M | $94.45M | $220.69M | $881.63M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 6.2% | 5.2% | 8.3% | 6.4% | 11.5% | 10.3% |
| EBITDA margin | 8.7% | 9.1% | 11.5% | 9.6% | 14.8% | 14.0% |
| Net margin | 2.7% | 4.1% | 3.7% | 2.5% | 6.5% | 4.7% |
| Free cash flow margin | 2.2% | 5.7% | 5.3% | 1.5% | 3.6% | 15.9% |
| FCF / Net income | 0.80 | 1.38 | 1.45 | 0.59 | 0.55 | 3.40 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 2.8% | 4.4% | 2.6% | 2.4% | 2.4% | 2.5% |
| Effective tax rate | 28.5% | 17.3% | 25.3% | 28.2% | 24.4% | 30.2% |
| Return on assets | 2.5% | 3.8% | 3.2% | 2.1% | 5.5% | 3.4% |
| Return on equity | 8.6% | 12.7% | 18.9% | 14.2% | 36.2% | 24.4% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.04 | 1.04 | 1.01 | 1.10 | 0.90 | 1.11 |
| Quick ratio | 1.04 | 1.04 | 1.01 | 1.10 | 0.90 | 1.11 |
| Cash ratio | 0.03 | 0.06 | 0.07 | 0.08 | 0.06 | 0.40 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 2.9x | 2.1x | 2.8x | 2.4x | 5.2x | 3.7x |
| Equity multiplier | 3.43 | 3.34 | 5.97 | 6.83 | 6.63 | 7.22 |
| Liabilities / Assets | 0.65 | 0.64 | 0.80 | 0.82 | 0.81 | 0.78 |
| Efficiency | ||||||
| Asset turnover | 0.93 | 0.92 | 0.87 | 0.83 | 0.84 | 0.72 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 58d | 58d | 52d | 54d | 52d | 59d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 12.8x | 11.4x | 12.3x | 20.2x | 9.9x | 14.3x |
| P / B | 1.1x | 1.4x | 1.2x | 1.5x | 1.9x | 1.8x |
| P / S | 0.3x | 0.5x | 0.2x | 0.3x | 0.3x | 0.3x |
| EV / EBITDA | 3.8x | 4.8x | 1.9x | 2.6x | 2.2x | 1.8x |
| Growth | ||||||
| Revenue growth (YoY) | 5.1% | -22.2% | 5.2% | 2.1% | 12.2% | 1.4% |
| Revenue CAGR (3y) | -4.9% | -5.8% | 6.4% | 5.1% | 13.7% | - |
| Revenue CAGR (5y) | -0.3% | -1.0% | 9.6% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 25.3% | -51.6% | 37.6% | -43.5% | 25.7% | 20.3% |
| Net income growth (YoY) | -31.7% | -12.1% | 53.1% | -60.5% | 55.3% | 74.5% |
| EPS growth (YoY) | -30.1% | 61.3% | 55.3% | -58.7% | 54.4% | -5.5% |
| EPS CAGR (3y) | 20.5% | 1.1% | -0.3% | -15.5% | 16.3% | -7.9% |
| EPS CAGR (5y) | 2.2% | 8.6% | 0.2% | -13.0% | 13.0% | 1.0% |
| FCF growth (YoY) | -60.3% | -16.2% | 273.6% | -57.2% | -75.0% | 206.1% |
| FCF CAGR (5y) | -33.2% | 0.5% | 1.5% | -3.6% | 3.6% | 102.7% |
| Book value growth (YoY) | 1.4% | 30.5% | 14.8% | 1.1% | 4.7% | 37.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$8.82B totalCritical Illness Recovery Hospital$2.48B · 28.1%
Critical Illness Recovery Hospitals$2.48B · 28.1%
Rehabilitation Hospital$1.29B · 14.6%
Rehabilitation Hospitals$1.29B · 14.6%
Outpatient Rehabilitation$1.28B · 14.6%
Product / service
$4.95B totalHealth Care Patient Service$2.47B · 50.0%
Health Care Patient Service Non Medicare$1.69B · 34.0%
Health Care Patient Service Medicare$788.43M · 15.9%
Service Other$4.00M · 0.1%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.42
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Hospitals
Comparing SELECT MEDICAL HOLDINGS CORP against the 3 most active filers in the same SIC group.
Dividends
$0.25/share trailing 12 months · -3.3% YoY
| Ex-date | Per share |
|---|---|
| May 14, 2026 | $0.0630 |
| Mar 2, 2026 | $0.0630 |
| Nov 12, 2025 | $0.0630 |
| Aug 13, 2025 | $0.0630 |
| May 15, 2025 | $0.0630 |
| Mar 3, 2025 | $0.0630 |
| Nov 13, 2024 | $0.0673 |
| Aug 14, 2024 | $0.0673 |
| May 15, 2024 | $0.0673 |
| Feb 29, 2024 | $0.0673 |
| Nov 14, 2023 | $0.0673 |
| Aug 14, 2023 | $0.0673 |
| May 17, 2023 | $0.0673 |
| Mar 2, 2023 | $0.0673 |
| Nov 15, 2022 | $0.0673 |
| Aug 15, 2022 | $0.0673 |
| May 18, 2022 | $0.0673 |
| Mar 3, 2022 | $0.0673 |
| Nov 15, 2021 | $0.0673 |
| Aug 17, 2021 | $0.0673 |
| May 18, 2021 | $0.0673 |
| Mar 2, 2015 | $0.0539 |
| Nov 17, 2014 | $0.0539 |
| Aug 18, 2014 | $0.0539 |